Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Pre-Clinical Study on the Dual BCL2/BCL-XL Inhibitor AZD0466 for the Treatment of Chronic Lymphocytic Leukemia

Billy Jebaraj, Rashmi Priyadharshini Dheenadayalan, Annika Müller, Jialei Qi, Eugen Tausch, Christof Schneider, Daniela Steinbrecher, Daniel Mertens, Felix Seyfried, Lüder Hinrich Meyer, André Lechel, Barbara F. Eichhorst, Courtney L Andersen, Giulia Fabbri, Stephan Stilgenbauer

Blood (2023) 142 (Supplement 1): 84.

https://doi.org/10.1182/blood-2023-188554

Published: 2023

Journal Articles

Acquired Venetoclax Resistance in an In Vivo Model of B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By Altered Functions of Apoptosis Regulators

Stefanie Enzenmüller, Alexandra Niedermayer, Felix Seyfried, Alexander Groß, Klaus-Michael Debatin, Lüder Hinrich Meyer

Blood (2023) 142 (Supplement 1): 1446.

https://doi.org/10.1182/blood-2023-185621

Published: 2023

Journal Articles

Identification of vulnerabilities for targeting BCL-2 family members in T-Cell Acute Lymphoblastic Leukemia

Colin Fortner, Maren Wichert, Alexandra Niedermayer, Klaus-Michael Debatin, Lüder Hinrich Meyer, Felix Seyfried

Blood (2023) 142 (Supplement 1): 1608.

https://doi.org/10.1182/blood-2023-177613

Published: 2023

Journal Articles

Venetoclax Resistance in B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By Increased Mitochondrial Metabolism and Can be Overcome By Co-Targeting Oxidative Phosphorylation

Alexandra Niedermayer, Stefanie Enzenmüller, Felix Seyfried, Daniel Tews, Pamela Fischer-Posovszky, Ulrich Rupp, Paul Walther, Klaus-Michael Debatin, Lüder Hinrich Meyer

Blood (2022) 140 (Supplement 1): 6358–6359.

https://doi.org/10.1182/blood-2022-166223

Published: 2022

Journal Articles

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

Billy Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan, Sascha Endres, Philipp M. Roessner, Felix Seyfried, Claudia Walliser, Martin Wist, Jialei Qi, Eugen Tausch, Daniel Mertens, Judith A. Fox, Klaus-Michael Debatin, Lüder Hinrich Meyer, Pietro Taverna, Martina Seiffert, Peter Gierschik, Stephan Stilgenbauer

Blood (2022) 139 (6): 859–875.

https://doi.org/10.1182/blood.2021011516

Published: 2022

Includes: Supplemental data

Journal Articles

MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia

Blood (2021) 138 (20): 1953–1965.

https://doi.org/10.1182/blood.2020007591

Published: 2021

Includes: Supplemental data

Journal Articles

Synergistic Activity of BH3-Mimetics By Combined Targeting of Anti-Apoptotic Regulators in B-Cell Precursor ALL

Felix Seyfried, Felix Stirnweiß, Alexandra Niedermayer, Stefanie Enzenmüller, Rebecca Hörl, Stefan Köhrer, Klaus-Michael Debatin, Lüder Hinrich Meyer

Blood (2021) 138 (Supplement 1): 706.

https://doi.org/10.1182/blood-2021-150162

Published: 2021

Journal Articles

Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Alexandra Niedermayer, MSc, Stefanie Enzenmüller, PhD, Eugen Tausch, Stephan Stilgenbauer, MD, Felix Seyfried, MD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD

Blood (2019) 134 (Supplement_1): 3954.

https://doi.org/10.1182/blood-2019-126582

Published: 2019

Journal Articles

Biomarker Profile for Prediction of Patient Response to Smac Mimetic Monotherapy in Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia

Julia Zinngrebe, MD, Ferdinand Schlichtig, Malcolm Meyer, Johann M. Kraus, Elena Boldrin, PhD, Hans A. Kestler, Lüder Hinrich Meyer, MD, Pamela Fischer-Posovszky, Klaus-Michael Debatin, MD

Blood (2019) 134 (Supplement_1): 2082.

https://doi.org/10.1182/blood-2019-130967

Published: 2019

Journal Articles

Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2

Daniela Steinbrecher, PhD, Felix Seyfried, MD, Eugen Tausch, Johannes Bloehdorn, MD, Billy Michael Chelliah Jebaraj, PhD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD, Christof Schneider, MD

Blood (2019) 134 (Supplement_1): 1507.

https://doi.org/10.1182/blood-2019-127931

Published: 2019

Journal Articles

Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option

Daniela Steinbrecher, MSc, Felix Seyfried, Johannes Bloehdorn, MD, Billy Michael Chelliah Jebaraj, PhD, Lüder Hinrich Meyer, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, Christof Schneider, MD

Blood (2018) 132 (Supplement 1): 1580.

https://doi.org/10.1182/blood-2018-99-115845

Published: 2018

Journal Articles

Synergistic Activity of the MCL-1-Specific Inhibitor S63845 with Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia

Felix Seyfried, Felix Stirnweiß, Stefan Köhrer, MD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD

Blood (2018) 132 (Supplement 1): 1416.

https://doi.org/10.1182/blood-2018-99-117139

Published: 2018

Journal Articles

FOXO1 Is Involved in the Regulation of B-Cell Precursor Acute Lymphoblastic Leukemia Survival and Serves As a Novel Target for Directed Therapy

Salih Demir, MSc, Fan Wang, Franziska Gehringer, Clarissa Weitzer, Klaus-Michael Debatin, MD PhD, Thomas Wirth, Prof. Dr., Lüder Hinrich Meyer, MD, Alexey Ushmorov, Dr.

Blood (2016) 128 (22): 4020.

https://doi.org/10.1182/blood.V128.22.4020.4020

Published: 2016

Journal Articles

Lysosomal Cell Death and Apoptosis Crosstalk - Synergistic Role in Bcl-2 Inhibitor (ABT-263) Mediated Cell Death in B-Cell Precursor Acute Lymphoblastic Leukemia

Stefanie Enzenmüller, PhD, Qian Sun, PhD, Klaus-Michael Debatin, MD PhD, Lüder-Hinrich Meyer, MD

Blood (2016) 128 (22): 1584.

https://doi.org/10.1182/blood.V128.22.1584.1584

Published: 2016

Journal Articles

Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199 in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By MCL-1/BCL-2 Expression Serving As Biomarker for Treatment Response

Felix Seyfried, MD, Salih Demir, MSc, Rebecca Hörl, Stefan Köhrer, Annika Scheffold, Stephan Stilgenbauer, Klaus-Michael Debatin, MD PhD, Lüder Hinrich Meyer, MD

Blood (2016) 128 (22): 1081.

https://doi.org/10.1182/blood.V128.22.1081.1081

Published: 2016

Journal Articles

TET1 Promotes Leukemic Growth in T-ALL Via Maintenance of 5-Hydroxymethylation Marks and Can be Antagonized By the PARP Inhibitor Olaparib

Deniz Sahin, M.Sc, Shiva Bamezai, PhD, Fabio Ciccarone, PhD, Elena Fischbein, MSc, Fabian Mohr, PhD, Medhanie A. Mulaw, Jun.-Prof. Dr., Alex Pulikkottil Jose, M.Sc, Paola Caiafa, MD, Lüder-Hinrich Meyer, MD, Klaus-Michael Debatin, Prof. Dr., Geertruy te Kronnie, PhD, Konstanze Döhner, Hartmut Döhner, Prof. Dr., Michaela Feuring-Buske, PD Dr., Christian Buske, Vijay P.S. Rawat, PhD

Blood (2016) 128 (22): 737.

https://doi.org/10.1182/blood.V128.22.737.737

Published: 2016

Journal Articles

Targeting Mutant p53 in Pediatric Acute Lymphoblastic Leukemia

Salih Demir, MSc, Galina Selivanova, PhD, Eugen Tausch, MD, Lisa Wiesmüller, PhD, Stephan Stilgenbauer, MDPhD, Geertruy Te Kronnie, PhD, Klaus-Michael Debatin, MDPhD, Lüder Hinrich Meyer, MD

Blood (2015) 126 (23): 903.

https://doi.org/10.1182/blood.V126.23.903.903

Published: 2015

Journal Articles

Immunoglobulin Heavy Chain (IgH) Knockout Inhibits Proliferation of Pre-BCR + B-Cell Acute Lymphoblastic Leukemia (B-ALL) Via a FOXO1 and MYC Dependent Mechanism

Stefan Koehrer, MD, Ondrej Havranek, MDPhD, R Eric Davis, MD, Felix Seyfried, MD, Greg Coffey, PhD, Ekaterina Kim, MS, Nathalie Y. Rosin, PhD, Elisa ten Hacken, PhD, Ulrich Jäger, MD, Katrina Vanura, PhD, Susan O'Brien, MD, Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Dipanjan Ghosh, PhD, Zhiqiang Wang, Lüder Hinrich Meyer, MD, Hassan Jumaa, PhD, Jan A. Burger, MDPhD

Blood (2014) 124 (21): 287.

https://doi.org/10.1182/blood.V124.21.287.287

Published: 2014

Journal Articles

Effective in Vivo Targeting of BCP-ALL in a NOD/SCID/huALL Mouse Model By CD70 Directed Immunotherapy

Qian Sun, PhD, Chiara Borga, PhD, Geertruy te Kronnie, PhD, Klaus-Michael Debatin, MDPhD, Lüder Hinrich Meyer, MD

Blood (2014) 124 (21): 970.

https://doi.org/10.1182/blood.V124.21.970.970

Published: 2014

Journal Articles

ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling

Lilian Kuster, Reinhard Grausenburger, Gerhard Fuka, Ulrike Kaindl, Gerd Krapf, Andrea Inthal, Georg Mann, Maximilian Kauer, Johannes Rainer, Reinhard Kofler, Andrew Hall, Markus Metzler, Lüder Hinrich Meyer, Claus Meyer, Jochen Harbott, Rolf Marschalek, Sabine Strehl, Oskar A. Haas, Renate Panzer-Grümayer

Blood (2011) 117 (9): 2658–2667.

https://doi.org/10.1182/blood-2010-03-275347

Published: 2011

Includes: Supplemental data

NARROW

Pre-Clinical Study on the Dual BCL2/BCL-XL Inhibitor AZD0466 for the Treatment of Chronic Lymphocytic Leukemia

Acquired Venetoclax Resistance in an In Vivo Model of B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By Altered Functions of Apoptosis Regulators

Identification of vulnerabilities for targeting BCL-2 family members in T-Cell Acute Lymphoblastic Leukemia

Venetoclax Resistance in B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By Increased Mitochondrial Metabolism and Can be Overcome By Co-Targeting Oxidative Phosphorylation

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia

Synergistic Activity of BH3-Mimetics By Combined Targeting of Anti-Apoptotic Regulators in B-Cell Precursor ALL

Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Biomarker Profile for Prediction of Patient Response to Smac Mimetic Monotherapy in Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia

Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2

Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option

Synergistic Activity of the MCL-1-Specific Inhibitor S63845 with Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia

FOXO1 Is Involved in the Regulation of B-Cell Precursor Acute Lymphoblastic Leukemia Survival and Serves As a Novel Target for Directed Therapy

Lysosomal Cell Death and Apoptosis Crosstalk - Synergistic Role in Bcl-2 Inhibitor (ABT-263) Mediated Cell Death in B-Cell Precursor Acute Lymphoblastic Leukemia

Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199 in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By MCL-1/BCL-2 Expression Serving As Biomarker for Treatment Response

TET1 Promotes Leukemic Growth in T-ALL Via Maintenance of 5-Hydroxymethylation Marks and Can be Antagonized By the PARP Inhibitor Olaparib

Targeting Mutant p53 in Pediatric Acute Lymphoblastic Leukemia

Immunoglobulin Heavy Chain (IgH) Knockout Inhibits Proliferation of Pre-BCR + B-Cell Acute Lymphoblastic Leukemia (B-ALL) Via a FOXO1 and MYC Dependent Mechanism

Effective in Vivo Targeting of BCP-ALL in a NOD/SCID/huALL Mouse Model By CD70 Directed Immunotherapy

ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only